Clinical Trial Update: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating spironolactone to prevent rash in patients with advanced cancer receiving panitumumab and cetuximab has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatologic Complication of Cancer Therapy
• Malignant Neoplasm

Drugs mentioned

• Cetuximab (cetuximab)
• Panitumumab (panitumumab)
• Spironolactone (spironolactone)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Advanced Malignant Neoplasm, Dermatologic Complication | Phase 2 | Status: COMPLETED | Results posted: 2020-01-09